evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC) Meeting Abstract


Authors: Mayer, E. L.; Tolaney, S. M.; Brufsky, A.; Gradishar, W. J.; Jhaveri, K. L.; Martin, M.; Moscetti, L.; Schneeweiss, A.; Vidal, G. A.; Cortazar, P.; Feldman, M.; Day, B.; Rugo, H. S.
Abstract Title: evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)
Meeting Title: 2023 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 41
Issue: 16 Suppl.
Meeting Dates: 2023 Jun 2-6
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2023-06-01
Language: English
DOI: 10.1200/JCO.2023.41.16_suppl.TPS1119
PROVIDER: EBSCOhost
PROVIDER: cinahl
DOI/URL:
Notes: Meeting Abstract: TPS1119 -- Meeting was also available virtually -- Source: Cinahl
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Komal Lachhman Jhaveri
    201 Jhaveri